Cargando…
Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine
BACKGROUND: Triple-negative breast cancer (TNBC) is defined by the absence of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Breast cancers with a BRCA1 mutation are also frequently triple-negative. Currently, there is a lack of effective therapi...
Autores principales: | Nhukeaw, Tidarat, Temboot, Pornvichai, Hansongnern, Kanidtha, Ratanaphan, Adisorn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933379/ https://www.ncbi.nlm.nih.gov/pubmed/24507701 http://dx.doi.org/10.1186/1471-2407-14-73 |
Ejemplares similares
-
Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib
por: Hongthong, Khwanjira, et al.
Publicado: (2021) -
A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer
por: Ratanaphan, Adisorn
Publicado: (2012) -
Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1
por: Ratanaphan, Adisorn, et al.
Publicado: (2014) -
In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein
por: Atipairin, Apichart, et al.
Publicado: (2011) -
Altered DNA Binding and Amplification of Human Breast Cancer Suppressor Gene BRCA1 Induced by a Novel Antitumor Compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)]
por: Chakree, Korawan, et al.
Publicado: (2012)